Talk:Idarucizumab

Wiki Education assignment: PHMD 2040 Service - Learning Fall 2023
— Assignment last updated by Balugaa3 (talk) 21:23, 30 April 2024 (UTC)

New Sections
I will be adding information for 3 new sections: mechanism of action, medical uses and adverse effects. The sources I'm using are DailyMed, 2 systematic reviews by van der Horst et. al and Thibault et. al, and clinical guidelines from Canada and the US. --Balugaa3 (talk) 05:29, 1 May 2024 (UTC)


 * Also, a new section called “Pharmacokinetics” should be added as there is evidence showing that marked decrease in renal function may decrease the effectiveness of idarucizumab. Dabigatran isn’t usually prescribed to those with low eGFR or severe CKD, but these findings are still relevant to patients on dabigatran who experience a sudden decline in renal function, like an acute kidney injury. The paper “Incomplete responses to the recommended dose of idarucizumab: a systematic review and pharmacokinetic analysis” by Athavale et. al (PMID: 32267185) illustrates this. Balugaa3 (talk) 20:13, 1 May 2024 (UTC)